Agence nationale de sécurité du médicament et des produits de santé

Agence nationale de sécurité du médicament et des produits de santé (ANSM) superseded the tasks and duties of Agence française de sécurité sanitaire des produits de santé (AFSSAPS) on 1 May 2012.[1] It is responsible for assessing the benefits and risks associated with the use of drugs and other medical products throughout their life-cycle. ANSM assesses the safety, efficacy and quality of these products and must balance patient safety with access to novel therapies.

Building of the ANSM in Paris

Agence française de sécurité sanitaire des produits de santé
Logo of the Agence française de sécurité sanitaire des produits de santé

The Agence française de sécurité sanitaire des produits de santé (French Agency for the Safety of Health Products), often abbreviated AFSSAPS or AFSSaPS, was a French government agency whose main mission was to assess health risks posed by health products intended for human consumption, particularly pharmaceutical drugs. It was responsible for issuing permits for marketing approval and became the single French authority in the regulation of biomedical research.

The agency was last headed by Dominique Maraninchi and had about 1,000 employees plus 2,000 associated experts. Its budget amounted to approximately 157 million euros, with the bulk of revenue came from taxes and charges levied on the activity of the pharmaceutical industry.

History

The Medicines Agency was created by law no. 93-5 of January 4, 1993 and decree no. 93-265 of March 8, 1993, notably following the contaminated blood affair. It became operational in April 1993, then the structure and organization of the agency were approved by the French government on September 2, 1993.[2]

Health data, publications

A list of 77 monitored drugs was published in 2011.[3]

In mid-December 2014, Health Insurance posted on www.data.gouv.fr 112 sets of open data, certified health data relating to the supply and consumption of healthcare in France, in order to improve transparency. drug prescription, traceability of active ingredients and their date of marketing.[4]

In September 2018, the ANSM prevented the transmission of information on Levothyrox to an association of victims, on the grounds of business secrecy.[5]

References
  1. Martine Lochouarn (2012-06-09). "France launches new drug regulatory agency". Lancet. The Lancet. 379 (9832): 2136. doi:10.1016/s0140-6736(12)60927-1. PMID 22690393. S2CID 32011295. Retrieved 2013-11-26.
  2. "Décret n°93-295 du 8 mars 1993 relatif à l'Agence du médicament créée par l'article L. 567-1 du code de la santé publique". www.legifrance.gouv.fr. Retrieved 2022-06-29.
  3. 77 médicaments surveillés : liste publiée, Le Figaro, 31 janvier 2011 lefigaro.fr
  4. Page des données Open data apportées par la Caisse nationale de l'assurance maladie des travailleurs salariés sur le portail Data.gouv.fr
  5. "Levothyrox : quand l'Agence du médicament se cache derrière le secret des affaires". Le Monde.fr. 2018-09-28. Retrieved 2018-11-28.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.